351 related articles for article (PubMed ID: 25054580)
1. Targeting of histone deacetylases in brain tumors.
Ecker J; Witt O; Milde T
CNS Oncol; 2013 Jul; 2(4):359-76. PubMed ID: 25054580
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; RodrÃguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
3. Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options.
Manou M; Kanakoglou DS; Loupis T; Vrachnos DM; Theocharis S; Papavassiliou AG; Piperi C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373187
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
Koutsounas I; Giaginis C; Theocharis S
World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
[TBL] [Abstract][Full Text] [Related]
6. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
7. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors in the treatment of hematological malignancies.
Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.
Xiang XS; Li PC; Wang WQ; Liu L
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922
[TBL] [Abstract][Full Text] [Related]
11. Advances in targeting histone deacetylase for treatment of solid tumors.
Shi MQ; Xu Y; Fu X; Pan DS; Lu XP; Xiao Y; Jiang YZ
J Hematol Oncol; 2024 May; 17(1):37. PubMed ID: 38822399
[TBL] [Abstract][Full Text] [Related]
12. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
Gryder BE; Sodji QH; Oyelere AK
Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
Miller CP; Singh MM; Rivera-Del Valle N; Manton CA; Chandra J
J Biomed Biotechnol; 2011; 2011():514261. PubMed ID: 21765634
[TBL] [Abstract][Full Text] [Related]
14. New and emerging HDAC inhibitors for cancer treatment.
West AC; Johnstone RW
J Clin Invest; 2014 Jan; 124(1):30-9. PubMed ID: 24382387
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone deacetylases in T-cell lymphoma.
Moskowitz AJ; Horwitz SM
Leuk Lymphoma; 2017 Jun; 58(6):1306-1319. PubMed ID: 27813438
[TBL] [Abstract][Full Text] [Related]
16. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
17. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
18. Novel histone deacetylase inhibitors for the treatment of pediatric brain tumors.
de Andrade PV; Andrade AF; Queiroz RG; Trevisan FA; Tone LG; Valera ET
Cent Nerv Syst Agents Med Chem; 2014; 14(2):90-5. PubMed ID: 25388206
[TBL] [Abstract][Full Text] [Related]
19. Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy.
Wu J; Nie J; Luan Y; Ding Y
Curr Med Chem; 2023; 30(20):2267-2311. PubMed ID: 36043742
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.
Ceccacci E; Minucci S
Br J Cancer; 2016 Mar; 114(6):605-11. PubMed ID: 26908329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]